Bruker Corporation $BRKR Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System boosted its position in Bruker Corporation (NASDAQ:BRKR) by 21.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,579 shares of the medical research company’s stock after buying an additional 21,552 shares during the period. California State Teachers Retirement System’s holdings in Bruker were worth $4,428,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Allworth Financial LP grew its position in shares of Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 257 shares during the period. Federated Hermes Inc. raised its holdings in shares of Bruker by 6.7% during the 4th quarter. Federated Hermes Inc. now owns 6,027 shares of the medical research company’s stock valued at $284,000 after buying an additional 380 shares in the last quarter. Parallel Advisors LLC lifted its position in Bruker by 121.0% in the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after buying an additional 479 shares during the last quarter. State of Michigan Retirement System boosted its stake in Bruker by 1.9% in the first quarter. State of Michigan Retirement System now owns 26,693 shares of the medical research company’s stock worth $964,000 after buying an additional 500 shares in the last quarter. Finally, CWM LLC boosted its stake in Bruker by 49.8% in the fourth quarter. CWM LLC now owns 1,631 shares of the medical research company’s stock worth $77,000 after buying an additional 542 shares in the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Price Performance

NASDAQ BRKR opened at $53.41 on Friday. The stock has a market capitalization of $8.13 billion, a price-to-earnings ratio of -76.30, a PEG ratio of 1.57 and a beta of 1.28. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $65.30. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.85 and a quick ratio of 0.72. The business’s fifty day moving average price is $58.50 and its 200-day moving average price is $46.80.

Bruker (NASDAQ:BRKR) last posted its earnings results on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.11. Bruker had a positive return on equity of 12.47% and a negative net margin of 2.35%.The company had revenue of $838.50 million for the quarter, compared to the consensus estimate of $853.57 million. During the same quarter in the prior year, the company earned $0.32 earnings per share. Bruker’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts predict that Bruker Corporation will post 2.12 earnings per share for the current year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 7th. Shareholders of record on Monday, June 22nd were issued a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend was Monday, June 22nd. Bruker’s dividend payout ratio is currently -28.57%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on BRKR shares. TD Cowen reaffirmed a “hold” rating on shares of Bruker in a research note on Wednesday, July 15th. Weiss Ratings upgraded Bruker from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, June 3rd. Citigroup dropped their price target on Bruker from $60.00 to $53.00 and set a “hold” rating on the stock in a research report on Wednesday. Leerink Partners upped their price target on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Finally, Zacks Research raised Bruker from a “hold” rating to a “strong-buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $56.64.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.